Product image of Ioduro (131i) De Sodio Curium Pharma Spain (Sodium Iodide (131i)) supplied by GNH India

Ioduro (131i) De Sodio Curium Pharma Spain

Active Ingredient:
Sodium Iodide (131i)
Origin:
EU

Ioduro (131i) De Sodio Curium Pharma Spain (Sodium Iodide (131i))

Sodium Iodide (I‑131), the active ingredient in Ioduro (131i) De Sodio, is a radioactive iodine drug presented as an oral radiopharmaceutical for oral use. It selectively destroys thyroid tissue and thyroid cancer cells, and is employed in patients with thyroid malignancies, hyperthyroidism, or after thyroidectomy to eliminate residual tissue.

GNH India supplies Ioduro (131i) De Sodio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across all markets, through robust quality‑assurance processes.

Manufacturer / TM Owner

Curium Pharma Spain

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Sodium Iodide (I‑131) is a radioactive iodine agent used in thyroid‑related conditions.

  • Thyroid cancer: eliminates residual or metastatic thyroid cancer cells after surgery.
  • Hyperthyroidism (e.g., Graves disease): ablates overactive thyroid tissue to restore normal hormone levels.
  • Post‑thyroidectomy ablation: destroys remaining thyroid tissue to facilitate complete remission and simplify subsequent hormone replacement.

How It Works

  • After oral administration, sodium iodide (I‑131) is actively taken up by the sodium‑iodide symporter in thyroid follicular cells. The isotope emits beta particles that cause localized radiation damage, leading to cellular necrosis and apoptosis of thyroid tissue and malignant cells, while gamma emissions allow imaging of distribution. This selective uptake spares non‑thyroid tissues and enables both therapeutic and diagnostic functions.

Side Effects

Sodium Iodide (I‑131) may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Nausea or vomiting
  • Dry mouth and altered taste
  • Neck pain or tenderness
  • Sialadenitis (inflammation of salivary glands)
  • Transient leukopenia
  • Fatigue or mild weakness

Serious or Rare Side Effects

  • Bone marrow suppression leading to pancytopenia
  • Severe radiation thyroiditis
  • Pulmonary fibrosis (radiation pneumonitis)
  • Secondary malignancies (e.g., leukemia)
  • Allergic reactions or anaphylaxis
  • Persistent hypothyroidism requiring lifelong hormone replacement

Precautions & Warnings

Before using Sodium Iodide (I‑131), several precautions should be observed to minimize risks.

  • Pregnancy status: confirm patient is not pregnant or assess risk‑benefit carefully.
  • Thyroid function: evaluate baseline thyroid hormone levels and adjust therapy accordingly.
  • Radiation safety: advise patient on minimizing radiation exposure to family and caregivers.
  • Hydration: ensure adequate fluid intake to promote renal clearance of radioiodine.
  • Blood counts: monitor complete blood count before and after treatment for hematologic effects.
  • Store at ambient temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Sodium Iodide (I‑131) can interact with other substances that affect iodine uptake or radiation response.

Major Interactions (Avoid)

  • Antithyroid drugs (e.g., methimazole, propylthiouracil): reduce iodine uptake and diminish therapeutic effect.
  • Lithium: increases retention of radioiodine in thyroid, raising radiation dose.
  • High‑iodine diet or iodine‑containing contrast agents: compete for uptake and lower efficacy.

Moderate Interactions (Monitor Closely)

  • Amiodarone: high iodine content may interfere with treatment; monitor thyroid function.
  • Diuretics (e.g., furosemide): may affect renal clearance of radioiodine.
  • Corticosteroids: may mask inflammatory responses; observe for delayed side effects.

Frequently Asked Questions

Ioduro (131i) De Sodio contains sodium iodide (I‑131) and is employed as a radiopharmaceutical to treat thyroid cancer, to ablate overactive thyroid tissue in hyperthyroidism such as Graves disease, and to eliminate residual thyroid tissue after thyroidectomy, facilitating complete disease control.

After oral ingestion, the sodium‑iodide symporter in thyroid cells concentrates the I‑131 isotope. The emitted beta particles cause localized radiation injury, destroying thyroid cells and malignant tissue, while gamma emissions enable imaging of distribution, providing both therapeutic and diagnostic benefits.

The prescribed activity is individualized by the treating physician based on factors such as the specific indication, patient weight, thyroid size, disease severity, and prior imaging results. No fixed dosing regimen can be provided without a medical assessment.

Radioactive iodine is generally contraindicated in pregnancy because it can cross the placenta and affect the fetal thyroid. Breastfeeding mothers should discontinue nursing for a period recommended by the physician, as the isotope can be secreted in breast milk.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Ioduro (131i) De Sodio delivers the same I‑131 isotope used in other branded or generic preparations. Differences may lie in manufacturing standards, regulatory approvals, and supply chain reliability. Clinically, efficacy and safety are comparable when administered at equivalent activities.

Store the product at ambient temperature, preferably below 25 °C, in its original sealed container. Protect it from moisture, direct sunlight, and physical damage to maintain radiochemical stability until the time of use.

The medication is taken orally, usually as a single dose in liquid or capsule form, under the supervision of a qualified nuclear medicine or endocrinology specialist. Patients are instructed on radiation safety measures and may be monitored in a controlled setting after administration.

Serious risks include bone marrow suppression leading to pancytopenia, severe radiation thyroiditis, pulmonary fibrosis from radiation exposure, secondary malignancies such as leukemia, and rare allergic reactions. Continuous monitoring of blood counts and clinical status is essential after therapy.

Patients who are pregnant, breastfeeding, have uncontrolled severe infections, or have a known hypersensitivity to iodine or radioactive substances should avoid this therapy. Additionally, individuals with inadequate renal function or those unable to comply with radiation safety precautions may be unsuitable candidates.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sodium Iodide (131i)

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT